CLINICAL_TRIALS
research
· 2026-02-23
Clinical Trial Update: Study of ALXN2220 Versus Placebo in Adults With ATTR-CM [Phase 3]
Summary
A Phase 3 trial comparing ALXN2220 to placebo in adults with transthyretin amyloid cardiomyopathy is ongoing but currently not recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Transthyretin Amyloid Cardiomyopathy | Phase 3 | Status: ACTIVE_NOT_RECRUITING